Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20266 Citations
ACE-031Small moleculeNo amino acid sequence. Icon reflects category theme only.ACE-031 traps myostatin to promote lean mass gains. Phase 1 showed 3.3% muscle increase from one injection, but vascular safety signals halted clinical development. Community protocols use doses far below trial levels. Quality verification is difficult for this recombinant fusion protein. (Word count: 42)
500mcg · Every 2 weeks
Summary: Add 1mL BAC water to your 1mg vial. Draw to 50.0 units on a U-100 syringe for a 500mcg dose. This vial will last 2 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 500mcg | Every 2 weeks |
| Moderate | 1mg | Every 2 weeks |
| Aggressive | 1,500mcg | Every 2 weeks |
ACE-031 is a large fusion protein, not a standard peptide. Reconstitution matters more here than with most compounds. For a 1 mg vial with 1 mL bacteriostatic water: concentration is 1000 mcg/mL. A 500 mcg dose is 50 units on an insulin syringe. A 1000 mcg dose uses the full vial. For a 5 mg vial with 2 mL bacteriostatic water: concentration is 2500 mcg/mL. A 500 mcg dose is 20 units. A 1000 mcg dose is 40 units. A 1500 mcg dose is 60 units. Add water slowly along the vial wall. Do not shake. ACE-031 is an 82 kDa protein that can denature with aggressive mixing; swirl gently until clear. If the solution looks cloudy or has particles after reconstitution, do not inject it. Protein aggregation means the compound may be damaged or degraded. The single biggest concern with ACE-031 is product authenticity. Standard HPLC purity testing tells you the mass is correct, not that the protein is properly folded and glycosylated. Request SDS-PAGE gel data from your supplier. If they can't provide it, you're guessing. (Word count: 186)
Dosing based on Dose extrapolated from Phase 1 single-dose study in healthy postmenopausal women (PMID 23616587) — 8 published references.View all sources →
Cross-check your ACE-031 reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
ACE-031 traps myostatin to promote lean mass gains. Phase 1 showed 3.3% muscle increase from one injection, but vascular safety signals halted clinical development. Community protocols use doses far below trial levels. Quality verification is difficult for this recombinant fusion protein. (Word count: 42)
